Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

January 31, 2018January 31, 2018

New T-cell Therapy Shows Promise in Epstein-Barr Virus-positive Hodgkin’s Lymphoma

News

A new type of T-cell-based cancer immunotherapy may offer hope to people with Epstein-Barr virus-positive Hodgkin’s lymphoma, a small clinical trial showed. Importantly, the therapy was designed for use without ... Read more

January 24, 2018January 26, 2018

EU Approves Adcetris for Certain Types of Cutaneous T-cell Lymphoma

News

The European Commission has approved Adcetris (brentuximab vedotin) as a treatment for adults with cutaneous T-cell lymphoma (CTCL) whose cancer produces the CD30 molecule. It had previously given the therapy ... Read more

January 23, 2018January 23, 2018

Adcetris Combo Effective as First-line Treatment for Hodgkin’s Lymphoma, Trial Results Show

News

Adcetris (brentuximab vedotin) in combination with chemotherapy is a valuable treatment option for patients with previously untreated advanced Hodgkin’s lymphoma, researchers said after revealing data from a Phase 3 clinical ... Read more

January 18, 2018January 18, 2018

FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) will prioritize the regulatory review of Novartis’ application to use Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large ... Read more

January 17, 2018January 17, 2018

New Blood Stem Cell Harvest Method Could Speed Up Transplants

News

A new method of releasing blood stem cells from the bone marrow into the blood may lead to more rapid and efficient stem cell transplants in lymphoma patients. If confirmed ... Read more

January 16, 2018January 16, 2018

New CAR T-cell Production Method May Offer Faster, More Targeted Therapies, Study Reports

News

A new method for growing the T-cells used in lymphoma immunotherapies may some day lead to treatments that are faster and do a better job of honing in on a ... Read more

January 15, 2018January 15, 2018

Age Alone Should Not Exclude Lymphoma Patients From Stem Cell Transplants, Researchers Argue

News

Older lymphoma patients should not be excluded from treatment with stem cell transplants based solely on their age, researchers at Massachusetts General Hospital have concluded after reviewing several patient outcomes. The ... Read more

January 9, 2018

FDA Cites Lack of Data About Blood Cancer Medications in Older People

News

Older patients are underrepresented in clinical trials of treatments for lymphoma and other blood cancers, despite being the largest patient group affected, researchers from the U.S. Food and Drug Administration ... Read more

January 4, 2018

Atara Starts Two Phase 3 Trials of Treatment for Lymphoma That Arises from a Transplant

News

Atara Biotherapeutics is conducting two Phase 3 clinical trials of a treatment for a transplant-related disorder that can include lymphoma. The company developed tabelecleucel (ATA129) for people whose dormant Epstein-Barr virus can ... Read more

December 19, 2017

Juno, Celgene Report Impressive Results of CAR T-cell Therapy in B-cell Lymphoma

News

The CAR T-cell therapy JCAR017, developed by Juno Therapeutics and Celgene, eradicated B-cell lymphomas in more than two-thirds of patients with high-risk cancer, the companies announced. The response to the ... Read more